CRSP240705C46000
- 6.69
- 0.000.00%
CRISPR Therapeutics Newsroom
Needham Reiterates Buy on CRISPR Therapeutics, Maintains $88 Price Target
CRISPR Therapeutics Analyst Ratings
Piper Sandler Reiterates Overweight on CRISPR Therapeutics, Maintains $105 Price Target
CRISPR Therapeutics Analyst Ratings
Needham Reiterates Buy on CRISPR Therapeutics, Maintains $88 Price Target
Analysts Offer Insights on Healthcare Companies: Medtronic (MDT), Crispr Therapeutics AG (CRSP) and Tango Therapeutics (TNGX)
Citi: Maintains CRISPR Therapeutics (CRSP.US) rating, adjusted from buy to buy rating, and adjusted the target price from $89.00 to $84.00.
CRISPR Therapeutics Analyst Ratings
Citigroup Maintains Buy on CRISPR Therapeutics, Lowers Price Target to $84
Stifel Nicolaus Sticks to Their Hold Rating for Crispr Therapeutics AG (CRSP)
Oppenheimer: The CRISPR Therapeutics (CRSP.US) rating was maintained, and the target price was adjusted from superior to superior market rating, and the target price was adjusted from $102.00 to $95.00.
CRISPR Therapeutics Analyst Ratings
Oppenheimer Adjusts CRISPR Therapeutics Price Target to $95 From $102, Maintains Outperform Rating
Barclays Adjusts Price Target on CRISPR Therapeutics to $67 From $80, Maintains Equal-Weight Rating
Cantor Fitzgerald Inc.: Reiterates CRISPR Therapeutics (CRSP.US) neutral rating.
Needham: Maintaining the CRISPR Therapeutics (CRSP.US) rating, adjusted from buy to buy rating, and adjusted the target price from $90.00 to $88.00.
RBC Capital Reaffirms Their Hold Rating on Crispr Therapeutics AG (CRSP)
CRISPR Therapeutics Analyst Ratings
Analysts Are Bullish on These Healthcare Stocks: Alnylam Pharma (ALNY), Crispr Therapeutics AG (CRSP)
CRISPR Therapeutics Analyst Ratings